Cargando…

Artificial Intelligence and the Future of the Drug Safety Professional

The healthcare industry, and specifically the pharmacovigilance industry, recognizes the need to support the increasing amount of data received from individual case safety reports (ICSRs). To cope with this increase, more healthcare and qualified professionals are required to capture and evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Danysz, Karolina, Cicirello, Salvatore, Mingle, Edward, Assuncao, Bruno, Tetarenko, Niki, Mockute, Ruta, Abatemarco, Danielle, Widdowson, Mark, Desai, Sameen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450851/
https://www.ncbi.nlm.nih.gov/pubmed/30343417
http://dx.doi.org/10.1007/s40264-018-0746-z
_version_ 1783409079223320576
author Danysz, Karolina
Cicirello, Salvatore
Mingle, Edward
Assuncao, Bruno
Tetarenko, Niki
Mockute, Ruta
Abatemarco, Danielle
Widdowson, Mark
Desai, Sameen
author_facet Danysz, Karolina
Cicirello, Salvatore
Mingle, Edward
Assuncao, Bruno
Tetarenko, Niki
Mockute, Ruta
Abatemarco, Danielle
Widdowson, Mark
Desai, Sameen
author_sort Danysz, Karolina
collection PubMed
description The healthcare industry, and specifically the pharmacovigilance industry, recognizes the need to support the increasing amount of data received from individual case safety reports (ICSRs). To cope with this increase, more healthcare and qualified professionals are required to capture and evaluate the data. To address the evolving landscape, it will be necessary to embrace assistive technologies such as artificial intelligence (AI) at scale. AI in the field of pharmacovigilance will possibly result in the transformation of the drug safety (DS) professional’s daily work life and their career development. Celgene’s Global Drug Safety and Risk Management (GDSRM) function has established a series of work activities to drive innovation across the pharmacovigilance value chain (Celgene Chrysalis Fact Sheet. https://www.celgene.com/newsroom/media-library/chrysalis-fact-sheet/, 2018). The development of AI in pharmacovigilance raises questions about the possible changes in DS professionals’ lives, who may find themselves curious about their future roles in a workplace assisted by AI. We discuss the current state of pharmacovigilance and the DS professional, AI in pharmacovigilance and the potential skillsets a DS professional may require when working with AI. We also describe the results of research conducted at Celgene GDSRM. The objective of the research was to understand the thoughts of pharmacovigilance professionals about their jobs. These results are provided in the form of aggregated responses to interview questions based on a 12-part questionnaire [see the Electronic Supplementary Material (ESM)]. A sample of six DS professionals representing various areas of pharmacovigilance operations were asked a range of questions about their backgrounds, current roles and future expectations. The DS professionals interviewed were, overall, enthusiastic about their job roles potentially changing with AI enhancements. Interviewees suggested that AI would allow for pharmacovigilance resources, time, and skills to shift the work from a volume-based to a value-based focus. The results suggest that pharmacovigilance professionals wish to use their qualifications, skillsets and experience in work that provides more value for their efforts. Machine learning algorithms have the potential to enhance DS professionals’ decision-making processes and support more efficient and accurate case processing. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40264-018-0746-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6450851
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-64508512019-04-17 Artificial Intelligence and the Future of the Drug Safety Professional Danysz, Karolina Cicirello, Salvatore Mingle, Edward Assuncao, Bruno Tetarenko, Niki Mockute, Ruta Abatemarco, Danielle Widdowson, Mark Desai, Sameen Drug Saf Current Opinion The healthcare industry, and specifically the pharmacovigilance industry, recognizes the need to support the increasing amount of data received from individual case safety reports (ICSRs). To cope with this increase, more healthcare and qualified professionals are required to capture and evaluate the data. To address the evolving landscape, it will be necessary to embrace assistive technologies such as artificial intelligence (AI) at scale. AI in the field of pharmacovigilance will possibly result in the transformation of the drug safety (DS) professional’s daily work life and their career development. Celgene’s Global Drug Safety and Risk Management (GDSRM) function has established a series of work activities to drive innovation across the pharmacovigilance value chain (Celgene Chrysalis Fact Sheet. https://www.celgene.com/newsroom/media-library/chrysalis-fact-sheet/, 2018). The development of AI in pharmacovigilance raises questions about the possible changes in DS professionals’ lives, who may find themselves curious about their future roles in a workplace assisted by AI. We discuss the current state of pharmacovigilance and the DS professional, AI in pharmacovigilance and the potential skillsets a DS professional may require when working with AI. We also describe the results of research conducted at Celgene GDSRM. The objective of the research was to understand the thoughts of pharmacovigilance professionals about their jobs. These results are provided in the form of aggregated responses to interview questions based on a 12-part questionnaire [see the Electronic Supplementary Material (ESM)]. A sample of six DS professionals representing various areas of pharmacovigilance operations were asked a range of questions about their backgrounds, current roles and future expectations. The DS professionals interviewed were, overall, enthusiastic about their job roles potentially changing with AI enhancements. Interviewees suggested that AI would allow for pharmacovigilance resources, time, and skills to shift the work from a volume-based to a value-based focus. The results suggest that pharmacovigilance professionals wish to use their qualifications, skillsets and experience in work that provides more value for their efforts. Machine learning algorithms have the potential to enhance DS professionals’ decision-making processes and support more efficient and accurate case processing. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40264-018-0746-z) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-10-20 2019 /pmc/articles/PMC6450851/ /pubmed/30343417 http://dx.doi.org/10.1007/s40264-018-0746-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Current Opinion
Danysz, Karolina
Cicirello, Salvatore
Mingle, Edward
Assuncao, Bruno
Tetarenko, Niki
Mockute, Ruta
Abatemarco, Danielle
Widdowson, Mark
Desai, Sameen
Artificial Intelligence and the Future of the Drug Safety Professional
title Artificial Intelligence and the Future of the Drug Safety Professional
title_full Artificial Intelligence and the Future of the Drug Safety Professional
title_fullStr Artificial Intelligence and the Future of the Drug Safety Professional
title_full_unstemmed Artificial Intelligence and the Future of the Drug Safety Professional
title_short Artificial Intelligence and the Future of the Drug Safety Professional
title_sort artificial intelligence and the future of the drug safety professional
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450851/
https://www.ncbi.nlm.nih.gov/pubmed/30343417
http://dx.doi.org/10.1007/s40264-018-0746-z
work_keys_str_mv AT danyszkarolina artificialintelligenceandthefutureofthedrugsafetyprofessional
AT cicirellosalvatore artificialintelligenceandthefutureofthedrugsafetyprofessional
AT mingleedward artificialintelligenceandthefutureofthedrugsafetyprofessional
AT assuncaobruno artificialintelligenceandthefutureofthedrugsafetyprofessional
AT tetarenkoniki artificialintelligenceandthefutureofthedrugsafetyprofessional
AT mockuteruta artificialintelligenceandthefutureofthedrugsafetyprofessional
AT abatemarcodanielle artificialintelligenceandthefutureofthedrugsafetyprofessional
AT widdowsonmark artificialintelligenceandthefutureofthedrugsafetyprofessional
AT desaisameen artificialintelligenceandthefutureofthedrugsafetyprofessional